Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus substantially reduced RSV lower respiratory tract.
Study demonstrated a 90% effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants, with a significant finding being the timely vaccination's role in offering protection.
Real World Data Shows RSV Shot Cut Infant Hospitalizations by 90% usnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usnews.com Daily Mail and Mail on Sunday newspapers.
Nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).